Table 2.
Treatment outcomes in afatinib and erlotinib arm
| Afatinib (%) | Erlotinib (%) | p-value | |
|---|---|---|---|
| Best response | 0.09 | ||
| CR | 0 (0.0) | 0 (0.0) | |
| PR | 5 (20.0) | 2 (7.1) | |
| SD | 12 (48.0) | 9 (32.1) | |
| PD | 8 (32.0) | 17 (60.7) | |
| Objective response rate | 5 (20.0) | 2 (7.1) | 0.17 |
| Disease control rate | 17 (68.0) | 11 (39.3) | 0.04 |
| Objective response of brain metastases | 3 (12.0) | 4 (14.3) | 0.81 |
| Median duration of treatment (months, range) | 4.5 (0.2–22.7) | 3.3 (0.3–48.7) | 0.52 |
| Median time to progression (months, range) | 3.3 (0.2–12.6) | 3.3 (0.3–14.4) | 0.77 |
| Median PFS (95 % CI) (months) | 4.1 (2.7–5.5) | 3.3 (2.2–4.4) | 0.97 |
| Median OS (95 % CI) (months) | 10.3 (7.5–13.0) | 10.8 (7.4–14.2) | 0.51 |
Abbreviations: CI confidence interval, CR complete response, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease, TKI tyrosine-kinase inhibitor